Henry Schein, Inc. reports developments across its health care distribution, practice solutions, and dental technology businesses. The company serves office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites through business, clinical, technology, and supply chain solutions.
Recurring news themes include earnings releases, financial guidance, investor conference participation, board and executive governance updates, and product announcements from Henry Schein One. Recent technology coverage centers on Dentrix Ascend, a cloud-based dental platform that integrates practice management, clinical workflows, imaging, revenue cycle management, analytics, patient experience tools, and AI-enabled workflow capabilities.
Henry Schein (Nasdaq: HSIC) will release its third quarter 2026 financial results before the market opens on November 3, 2026. Its earnings conference call will be webcast live at 8:00 a.m. Eastern time that day through the investor website, with a replay available afterward.
Henry Schein (Nasdaq: HSIC) named Emmanuel Caprais as Senior Vice President and Chief Financial Officer, effective November 4, 2026. Caprais will begin as Senior Financial Advisor on October 12, 2026, to support the transition. He will join the Henry Schein Leadership Team and report to CEO Frederick M. Lowery.
Current CFO Ronald N. South will move into a senior advisory role on November 4, 2026, after 18 years with the company. Caprais served as ITT’s CFO from 2020 until May 2026. Henry Schein also anticipates adding a Chief Strategy and Transformation Officer and a technology leadership position covering AI implementation, data and broader technology needs.
Henry Schein (HSIC) is marking 25 years of Henry Schein Cares, its global corporate citizenship program launched in 2001. Since its launch, the program has contributed more than $285 million in cash and donated products and collaborated with more than 5,000 charitable partners worldwide. It has delivered over 100,000 hygiene kits through the We Care Global Challenge and supported more than 75,000 students through its Back to School program.
A September 23 anniversary event in New York City previewed future priorities, including access to care, dental-medical integration and disaster preparedness. Henry Schein is targeting 100% renewable energy by 2030, currently achieving 34% through renewable energy certificates. It is also partnering with Climeworks Solutions to invest in its first carbon removal portfolio as part of efforts toward its Net Zero 2050 goal.
Henry Schein (HSIC) will present at the Baird Global Healthcare Conference at the InterContinental Hotel in New York City on September 15, 2026, at 12:15 p.m. EDT.
The presentation can be accessed via live webcast at the company’s investor relations webcast page, with replays available on Henry Schein’s website after the event.
Henry Schein (Nasdaq: HSIC) reported Q2 2026 net sales of $3.46 billion, up 6.7% year over year, driven by 4.6% internal growth, 0.7% from acquisitions, and 1.4% from foreign exchange. GAAP diluted EPS rose to $0.82 from $0.70, and non-GAAP diluted EPS increased to $1.27 from $1.10. Adjusted EBITDA reached $288 million versus $256 million a year ago.
For the first half of 2026, sales grew 6.5% to $6.83 billion and GAAP diluted EPS rose to $1.74. Henry Schein raised 2026 guidance to non-GAAP diluted EPS of $5.29–$5.39, total sales growth of 4.5%–5.5%, and mid- to high-single-digit Adjusted EBITDA growth. The company repurchased $200 million of stock in Q2 and $325 million year-to-date, with $455 million remaining authorized.
Henry Schein (Nasdaq: HSIC) announced a major leadership reorganization, creating the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee and integrating its global supply chain organization with its global distribution group.
The new structure is intended to support strategic priorities, faster decision-making, and a more customer-centric operating model. Effective October 30, 2026, Executive Vice President & COO Michael S. Ettinger, Executive Vice President & Chief Strategy Officer Mark E. Mlotek, and Senior Vice President, Global Supply Chain James (“Jim”) Mullins will transition out of their current roles and, from October 31, 2026, continue as Senior Advisors to the company.
Henry Schein (Nasdaq: HSIC) will release its second quarter 2026 financial results before the U.S. market opens on Tuesday, August 4, 2026, followed by a live earnings conference call webcast at 8:00 a.m. Eastern time. The call will feature CEO Fred Lowery and CFO Ronald N. South and will be accessible, along with a replay, via the company’s investor relations website.
GoTu Technology and Henry Schein (Nasdaq: HSIC) announced a strategic partnership to help dental practices address staffing shortages nationwide. GoTu’s technology-enabled marketplace will become part of Henry Schein Dental Recruitment Services, expanding access to temporary and permanent hygienists, assistants, and associate dentists.
The collaboration combines GoTu’s platform, which has filled more than 500,000 shifts, with Henry Schein’s broad customer network to offer flexible staffing solutions aimed at improving practice efficiency and continuity of patient care.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.
Henry Schein One (NASDAQ:HSIC) released its 2026 Catalyst Index, a benchmarking report for DSOs, multi-location groups, and private practices. The data indicates that clinical performance and case acceptance, not scale alone, drive predictable growth, with top performers achieving 75% case acceptance vs. a 45% industry average.
The Index also shows patient retention declining from 72% to 64% year over year, suggesting operational efficiency gains are not translating into long-term loyalty. The report is available in tailored editions for DSOs and private practices and debuts at CDA Anaheim.